REFERENCES
1. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142-7.
2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231-43.
3. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-11.
4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91.
5. Elzeneini M, Assaf Y, Aalaei-Andabili SH, Mahmoud A, Hamburger R, Goel R, et al. Predictors of ventricular pacing burden after permanent pacemaker implantation following transcatheter aortic valve replacement. Clin Cardiol. 2020.
6. Ravaux JM, Di Mauro M, Vernooy K, Kats S, Mariani S, Ronco D, et al. Permanent pacemaker implantation following transcatheter aortic valve implantation using self-expandable, balloon-expandable, or mechanically expandable devices: a network meta-analysis. Europace. 2021;23(12):1998-2009.
7. Bisson A, Bodin A, Herbert J, Lacour T, Saint Etienne C, Pierre B, et al. Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis. J Am Heart Assoc. 2020;9(9):e015896.
8. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125(1):76-86.
9. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573-7.
10. Avci A, Elnur A, Goksel A, Serdar F, Servet I, Atilla K, et al. The relationship between neutrophil/lymphocyte ratio and calcific aortic stenosis. Echocardiography. 2014;31(9):1031-5.
11. Cho KI, Cho SH, Her AY, Singh GB, Shin ES. Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis. PLoS One. 2016;11(8):e0161530.
12. Reinders A. DVCS, Joubert G. Pre-interventional assessment and calcification score of the aortic valve and annulus, with multi-detector CT, in transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve. S Afr J Rad. 2015.
13. Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, et al. Inverse Relationship Between Membranous Septal Length and the Risk of Atrioventricular Block in Patients Undergoing Transcatheter Aortic Valve Implantation. JACC Cardiovasc Interv. 2015;8(9):1218-28.
14. Cote N, Mahmut A, Bosse Y, Couture C, Page S, Trahan S, et al. Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation. 2013;36(3):573-81.
15. Stone PA, Kazil J. The relationships between serum C-reactive protein level and risk and progression of coronary and carotid atherosclerosis. Semin Vasc Surg. 2014;27(3-4):138-42.
16. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;50(20):1992-8.
17. Imai K, Okura H, Kume T, Yamada R, Miyamoto Y, Kawamoto T, et al. C-Reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis. Am Heart J. 2008;156(4):713-8.
18. Iglesias-Alvarez D, Lopez-Otero D, Gonzalez-Ferreiro R, Sanmartin-Pena X, Cid-Alvarez B, Trillo-Nouche R, et al. Prognostic Value of hs-CRP After Transcatheter Aortic Valve Implantation. Circ Cardiovasc Interv. 2018;11(12):e007213.
19. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269-85.